ALKERMES | ALKS - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 6.57B 2.82B 2026-06
Acadia Pharmaceuticals USD 956.47M 105.02M 2026-06
ALKERMES USD 511.53M 159.98M 2026-06
Amgen USD 13.99B 1.95B 2026-06
Biogen USD 1.28B 2.1B 2026-06
BioMarin Pharmaceutical USD 874M 1.35B 2026-06
Bristol-Myers Squibb USD 8.72B 852M 2026-06
Coherus Biosciences USD 82.92M 32.32M 2026-06
Eli Lilly USD 8.95B 3.67B 2026-06
Gilead Sciences USD 7.63B 64M 2026-03
Heron Therapeutics USD 20.72M 5.4M 2026-06
Ionis Pharmaceuticals USD 350.06M 1.57B 2026-06
J&J USD 20.42B 1.27B 2026-06
Malin Corporation EUR 62.1M 26.4M 2024-12
Merck USD 6.85B 1.52B 2026-06
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Nektar Therapeutics USD 149.58M 134.46M 2026-03
Neurocrine Biosciences USD 332.4M 65.9M 2026-06
Otsuka Holdings JPY 534.64B 123.53B 2025-12
Pfizer USD 976M 727M 2026-06
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Vertex Pharmaceuticals USD 7.85B 605.7M 2026-06